<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!-- SERVER: ecapp1003p.utd.com -->
<!-- layoutProfViewTopic -->
<html class="smartSearchUIEnabled ui-en js flexbox canvas canvastext webgl no-touch geolocation postmessage no-websqldatabase indexeddb hashchange history draganddrop websockets rgba hsla multiplebgs backgroundsize borderimage borderradius boxshadow textshadow opacity cssanimations csscolumns cssgradients no-cssreflections csstransforms csstransforms3d csstransitions fontface video audio localstorage sessionstorage webworkers applicationcache svg inlinesvg smil svgclippaths ie-standards"><head>
	



<title>Adjuvant systemic therapy in resectable non-small cell lung cancer</title>




	




<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta name="copyright" content="2014 UpToDate">

<meta name="description" content="Patients with stage I, II, or IIIA () non-small cell lung cancer (NSCLC) are at substantial risk for recurrence and death even after complete surgical resection. Approximately 40 to 50 percent of patients with stage IB, 55 to 70 percent of stage II, ">	
<meta name="keywords" content="International Adjuvant Lung Cancer Trial, Meta-analysis of Lung Adjuvant Cisplatin Evaluation, Adenocarcinoma of the lung, Adjuvant therapy, Bestatin, Large cell carcinoma of the lung, Lung cancer, Neoadjuvant or adjuvant chemotherapy in patients with operable non-small cell lung cancer trial, Non-small cell lung carcinoma, RADIANT trial of adjuvant erlotinib in non-small cell lung cancer, Squamous cell carcinoma of the lung, Tegafur uracil, Adjuvant chemotherapy, Excision repair cross complementation group 1 gene, Hepatitis B virus, Hepatitis B virus reactivation, Adjuvant Online calculator for lung cancer, American Society of Clinical Oncology guidelines, Bacillus Calmette-Guerin, Bacillus Calmette-Guerin vaccine, Cancer Care Ontario Practice Guidelines, Carboplatin, Chemotherapy, Cisplatin, Cyclophosphamide, Cyclophosphamide doxorubicin cisplatin, Docetaxel, Doxorubicin, Elderly, Fluorouracil, Gemcitabine, Gene expression profiling, Geriatric oncology, Immunotherapy, KRAS oncogene, Lobectomy, Lung Cancer Study Group trial, Lung cancer recurrence, National Comprehensive Cancer Network, Nitrosoureas, Paclitaxel, Postoperative radiation therapy, Radiation therapy, Surgery, Thoracic surgery, Thoracotomy, Thymidylate synthetase, Uracil, Vinca alkaloids, Vincristine, Vinorelbine, Vinorelbine cisplatin, p53 tumor suppressor gene">	






	<link rel="shortcut icon" href="http://www.uptodate.com/images/favicon.ico" type="image/x-icon">
	<link rel="icon" href="http://www.uptodate.com/images/favicon.ico" type="image/x-icon">


<link rel="search" type="application/opensearchdescription+xml" title="UpToDate Search Plugin" href="http://www.uptodate.com/xml/search.xml">













<link rel="stylesheet" type="text/css" href="Adjuvant%20systemic%20therapy%20in%20resectable%20non-small%20cell%20lung%20cancer_files/jquery-ui-1.css">


<link rel="stylesheet" type="text/css" href="Adjuvant%20systemic%20therapy%20in%20resectable%20non-small%20cell%20lung%20cancer_files/common.css">


<link rel="stylesheet" type="text/css" href="Adjuvant%20systemic%20therapy%20in%20resectable%20non-small%20cell%20lung%20cancer_files/search.css">


	
	
	<link rel="stylesheet" type="text/css" href="Adjuvant%20systemic%20therapy%20in%20resectable%20non-small%20cell%20lung%20cancer_files/layoutProfViewTopic.css">







	
	<link rel="stylesheet" type="text/css" href="Adjuvant%20systemic%20therapy%20in%20resectable%20non-small%20cell%20lung%20cancer_files/topic.css">















<!-- IMM061413#US4054 >>> New beta footer CSS &  -->


	
	<link rel="stylesheet" type="text/css" href="Adjuvant%20systemic%20therapy%20in%20resectable%20non-small%20cell%20lung%20cancer_files/profFooter.css">
	
	
	<link rel="stylesheet" type="text/css" href="Adjuvant%20systemic%20therapy%20in%20resectable%20non-small%20cell%20lung%20cancer_files/common-overrides.css">
	
	
	<link rel="stylesheet" type="text/css" href="Adjuvant%20systemic%20therapy%20in%20resectable%20non-small%20cell%20lung%20cancer_files/search-overrides.css">
	
	
		
		<link rel="stylesheet" type="text/css" href="Adjuvant%20systemic%20therapy%20in%20resectable%20non-small%20cell%20lung%20cancer_files/topic-overrides.css">
	

<!-- <<< IMM061413#US4054 -->








	
	
		<link rel="stylesheet" media="print" type="text/css" href="Adjuvant%20systemic%20therapy%20in%20resectable%20non-small%20cell%20lung%20cancer_files/print.css">
	

	

<link rel="stylesheet" media="print" type="text/css" href="Adjuvant%20systemic%20therapy%20in%20resectable%20non-small%20cell%20lung%20cancer_files/printPreview.css">



<!-- IMM062012#US317/TA667/A#236 > Adding CSS for Fancybox -->

<link rel="stylesheet" type="text/css" href="Adjuvant%20systemic%20therapy%20in%20resectable%20non-small%20cell%20lung%20cancer_files/jquery.css">
<!-- <<< IMM062012#US317/TA667/A#236 -->


<!-- Adding for IE9 gradient support -->
<!--[if gte IE 9]>
  <style type="text/css">
    .gradient {
       filter: none;
    }
  </style>
<![endif]-->














	
	<script type="text/javascript" src="Adjuvant%20systemic%20therapy%20in%20resectable%20non-small%20cell%20lung%20cancer_files/utd.js"></script>



<script type="text/javascript">
	$(document).ready(function() {
		$$.init({
			contextPath: '',
			topicType: 'MEDICAL_REVIEW',
			topicClass: 'MEDICAL',
			topicKey: 'lung_ca/8038',
			topicLanguage : 'en-US',
			pageType: 'TOPIC_PROFESSIONAL',
			imageKey: '',
			imageTitle: '',
			searchTerm: 'lung cancer treatment',
			isPrintView: false,		
			isSearchResults: false,
			tabId: '',
			onReadyUrl: '/services/AutoComplete',
			showSurvey: 
			false,
			locale: 'en',
			 removeTxt: 'Remove',
			exportPowerpoint: true
			 ,
			 userEngagement: 
			 	true,			 	
			acceptUrl: '/services/AgreementWebService?type=accept',
			declineUrl: '/home/contact-us',
			licenseUrl: '/contents/license',
			autoCompleteLength: '{"latinLength":1,"nonLatinLength":1}',
			providerTranslationURL: '',
			translation: "",
			detectedLang: 'en',
			uiClickEventUrls: 'http://www.healthlanguage.com/,http://www.provationordersets.com/,^/contents/practice-changing-updates,http://www.lexi.com/,/home/policies,/home/help-demo$,/home/uptodate-mobile-access,/contents/license,^http://www.linkedin.com/company/uptodate,https://www.facebook.com/UpToDateEBM,http://www.wolterskluwerhealth.com/,^/account/index,https://twitter.com/UpToDate,/home/training-resource-center,http://pharmacyonesource.com/,/contents/drug-interaction,http://www.provationmedical.com/,/home/contact-us,http://www.factsandcomparisons.com/,^/account/cme/process,/home/help$,http://www.medicom.com.cn/,http://www.medispan.com/,http://learn.uptodate.com/global,^/contents/table-of-contents/([^/]+)$,http://www.youtube.com/uptodateebm',
			smartSearchUIView: 'SMART_SEARCH',
			searchResultsState: 'EXPANDED',
			searchResultsOutline: true
			 
		});
	});
	
	var charRemainingMessage = 'characters remaining';
</script>


	
	<script type="text/javascript">
		$(document).ready(function() {
			$.extend($$.cme, {
				isTrack: true,
				lastTopicViewedDatabaseId: "14592376201"			
			});
			
			topicOnLoad(); 
		});
	</script>
<script src="Adjuvant%20systemic%20therapy%20in%20resectable%20non-small%20cell%20lung%20cancer_files/sat.js" type="text/javascript"></script><iframe height="0" width="0"></iframe><img src="Adjuvant%20systemic%20therapy%20in%20resectable%20non-small%20cell%20lung%20cancer_files/PageHit.gif" style="display:none" alt="" width="0"></head>






<body class="localization tl-en-US">




<script type="text/javascript">

	$$.inlineInitCustomer(true
	);
	var quirksmode = document.compatMode == "CSS1Compat";
	if (quirksmode) {
		$("html").addClass("ie-standards");
	}
</script>




		<div id="message-wrap">
			<div id="message-bg"></div>
			<iframe id="message-bk"></iframe>
			<dl id="message-container">
				<dt id="message-title"></dt>
				<dd id="message-body"></dd>
				<dd id="message-controls"></dd>
			</dl>
		</div>















<div id="topPanel">
	<div id="header">
		
		
			
			<div id="header2">
			






<div id="tier1">
	<div id="tier1_content">
		<div id="headerLogo">
			<a href="http://www.uptodate.com/contents/search">
				<img src="Adjuvant%20systemic%20therapy%20in%20resectable%20non-small%20cell%20lung%20cancer_files/UTD3_masthead.png" alt="UpToDate" height="30" width="115">
			</a>
			






		</div>
		<div id="headerLinks">
			


<div class="hidden">
	<div id="setLanguageContainer">
		<div id="setLanguageHeader">Search in your own language:</div>
		<div id="setLanguageContent">
		<form method="post" action="">
			<div class="searchLangText">UpToDate allows you to search in the languages below.  
				Please select your preference.  Topics will continue to be in English.
			</div>
			
			
			<div id="supported_languages">
			<ul id="supported_languages_left">
			
				
					
					<li id="zh-Hans">
					<a class="langpic lngsel-zh-Hans" href="">简体中文</a>
					
						<div class="clear"></div>
					</li>
			
				
					
					<li id="zh-Hant">
					<a class="langpic lngsel-zh-Hant" href="">繁體中文</a>
					
						<div class="clear"></div>
					</li>
			
				
					
					<li id="de">
					<a class="langpic lngsel-de" href="">Deutsch</a>
					
						<div class="clear"></div>
					</li>
			
				
					
					<li id="en" class="active">
					<a class="langpic lngsel-en" href="">English</a>
					
						<div class="clear"></div>
					</li>
			
				
					
					<li id="es">
					<a class="langpic lngsel-es" href="">Español</a>
					
						<div class="clear"></div>
					</li>
			
				
					</ul>
					<ul id="supported_languages_right">
				
					
					<li id="fr">
					<a class="langpic lngsel-fr" href="">Français</a>
					
						<div class="clear"></div>
					</li>
			
				
					
					<li id="it">
					<a class="langpic lngsel-it" href="">Italiano</a>
					
						<div class="clear"></div>
					</li>
			
				
					
					<li id="ja">
					<a class="langpic lngsel-ja" href="">日本語</a>
					
						<div class="clear"></div>
					</li>
			
				
					
					<li id="ko">
					<a class="langpic lngsel-ko" href="">한국어</a>
					
						<span class="redBeta">*</span>
					
						<div class="clear"></div>
					</li>
			
				
					
					<li id="pt">
					<a class="langpic lngsel-pt" href="">Português</a>
					
						<div class="clear"></div>
					</li>
			
			</ul>
			</div>
			<div class="clear"></div>
			<span class="redBeta">*Currently in beta testing.</span>		
			<div id="setLanguageButtons">
				<input id="setLanguageSubmit" class="submit" value="Submit" type="submit">
				<input id="setLanguageCancel" value="Cancel" type="submit">
			</div>
		</form>
		</div>
	</div>
</div>

			<a id="headerLanguage" href="#setLanguageContainer" class="setFBLanguage">Languages</a>
			<a id="headerHelp" href="http://www.uptodate.com/home/help" target="_blank">Help</a>
		</div>
	</div>
</div>
			






<div id="tier2">
	<div id="tier2_content">
		<p>
			<strong>Welcome,</strong>
			
			
			
				
										
				
			
			
			
			
			<a href="http://www.uptodate.com/account/index" id="nameLink">
			Anthony Rifkin  
			
			</a>
			
		</p>
		<div id="rightLinks">
			
				<a href="http://www.uptodate.com/account/index" id="myAccountLink">My Account</a>
			
			
				
				
				
				
					
					
						
					
					
				
				<a href="http://www.uptodate.com/account/cme/process">CME 6.5</a>
			
			
				
				<a id="headerLogin" href="http://www.uptodate.com/logout">Log Out</a>
			
			
		</div>
	</div>
</div>
			






<div style="width: auto;" id="tier3">
	<div id="tier3_content">
		<div id="topSearchBar" class="wideSearch">
			
			
			<form name="SearchForm" method="get" action="/contents/search">
				<div id="smallSearchBox">
					











	
	
		
		
			
		
		
		
	









	


<div id="new_search">
	<div style="width: 462px;" id="searchbox_dd">
		
			<span id="searchbox_dd_submit" title="Search">Search</span>
		
		
		<span id="searchbox_dd_type" title="Change Search Type">
			<span id="searchbox_dd_type_name">All Topics</span>
		</span>
		<div id="box">
			
				
					<input style="width: 342px;" id="txtSearch" name="search" maxlength="200" value="lung cancer treatment" autocomplete="off" placeholder="" type="text">
				
				
			
			<span id="iSearchTerm"></span>
		</div>
	</div>
	
		
	
	<input id="spinput" name="sp" value="0" type="hidden">
	<!-- the real searchType input, value is copied from above radio buttons with jquery
		because the radio buttons are moved outside of the form (for display purposes) -->
	<input id="searchType" name="searchType" value="0" type="hidden">
	<input name="source" value="USER_INPUT" id="source" type="hidden">
	<input name="searchControl" value="TOP_PULLDOWN" id="searchControl" type="hidden">
	<input name="searchOffset" value="" type="hidden">
	
</div>



				</div>
			</form>
			
			<a id="browseTab" href="http://www.uptodate.com/contents/table-of-contents">Contents</a>
			
		</div>
		<div id="headerMenuWrap">
			<div id="headerMenu">
				<ul id="header2_nav">
					<li id="overflowMenu" style="display: none;"></li>
					<li id="lexiTab"><a href="http://www.uptodate.com/contents/drug-interaction" target="_blank" style="padding-right: 0px;">Drug Interactions</a></li>
					<li id="calcTab"><a href="http://www.uptodate.com/contents/table-of-contents/calculators">Calculators</a></li>
					<li id="pcus"><a href="http://www.uptodate.com/contents/practice-changing-updates" title="Practice Changing Updates">PCUs</a></li>
					<li id="whatsNewTab"><a href="http://www.uptodate.com/contents/table-of-contents/whats-new">What's New</a></li>
					<li class="firstnav" id="patientInfoTab"><a href="http://www.uptodate.com/contents/table-of-contents/patient-information">Patient Info</a></li>
				</ul>
			</div>
		</div>
	</div>
</div>
			</div>
			
			
		
		
		











<div id="greyBar">
	<!--<div id="greyBarWrap">-->
		<div id="greyBarTitle"><span class="emphasis">Adjuvant systemic therapy in resectable non-small cell lung cancer</span></div>
		<div id="greyBarButtons">
		<!-- <a href="#" onclick="javascript:$('body').removeClass('fontSmall fontMed fontLarge').addClass('fontSmall');return false;" id="fontSmall" class="fontControl" title="Smaller Font"></a><a href="#" onclick="javascript:$('body').removeClass('fontSmall fontMed fontLarge').addClass('fontMed');return false;" id="fontMed" class="fontControl" title="Normal Font"></a><a href="#" onclick="javascript:$('body').removeClass('fontSmall fontMed fontLarge').addClass('fontLarge');return false;" id="fontLarge" class="fontControl" title="Larger Font"></a>-->
		
			
			
			<div id="fitHBW">
				<input id="findInPageGBBox" class="fitBox" size="24" value="lung cancer treatment" autocomplete="off" type="text">
			</div>
			<a class="findInPageLink icontxt buttonLink" href="#" title="Find in Topic">Find</a>
			
		
		
			
			<a href="#PATIENT_INFORMATION" class="patientInformationLink icontxt textLink" title="Patient Info">Patient </a>
		
		
			
			  
				
			
			
			
			  
				
			
			
			  
				
			
			
			  
				
			
			
		
		
			
			<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer?topicKey=ONC%2F4636&amp;elapsedTimeMs=14&amp;source=see_link&amp;view=print&amp;displayedView=full" class="icontxt textLink" title="Print This Topic">Print</a>
		
		
			
			<a class="icontxt textLink etacLink" href="#" title="Email This Topic">Email</a>
		
		</div>
	<!-- </div> -->
</div>
















	

		



		



<!-- menuMessage.jsp -->


<!-- /menuMessage.jsp -->
	
	</div> <!-- header -->
</div> <!-- topPanel -->
<div id="rightPanel">
	
<noscript>
<div id="javascriptDisabled">
It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.
</div>
</noscript>
	 



<div id="printHeader">
	<div id="printHeaderLogo">	

	<img src="Adjuvant%20systemic%20therapy%20in%20resectable%20non-small%20cell%20lung%20cancer_files/UTD3_masthead.png" class="imageLeft" alt="UpToDate">
	
	

	<img src="Adjuvant%20systemic%20therapy%20in%20resectable%20non-small%20cell%20lung%20cancer_files/logoWKH.gif" class="imageRight" alt="Wolters Kluwer Health" align="right" height="40" width="175">

	
	
		<div id="printHeaderText"> Official reprint from  UpToDate<sup>®</sup> <br><a href="http://www.uptodate.com/">www.uptodate.com</a>
			©2014 UpToDate<sup>®</sup>
		</div>
	
	
		
	</div> 


	<div id="printHeaderLinks">		
		
		
			<a id="printHeaderPrint" rel="14" class="TOPIC" href="#" title="Click here to print">Print</a>
		
		
		
		
			<span class="pipeSpace">|</span>
			<a id="printHeaderBack" href="#" title="Back to normal view">Back</a>
		
	</div>
</div>

	
<!-- TC:TOPIC_PAGE -->
	<div id="topicContent">
		
















	
	
		
	













	
	
		
			
			
				<div id="topicTitle"><div id="topicTitle">Adjuvant systemic therapy in resectable non-small cell lung cancer</div></div>
				
					<div id="topicContributors">
					<div><a id="authors"></a><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/contributors" class="contributor contributor_credentials contributorType">Author</a><br><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/contributors" class="contributor contributor_credentials">Nasser Hanna, MD</a><br></div><div><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/contributors" class="contributor contributor_credentials contributorType">Section Editors</a><br><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/contributors" class="contributor contributor_credentials">Rogerio C Lilenbaum, MD, FACP</a><br><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/contributors" class="contributor contributor_credentials">James R Jett, MD</a><br></div><div><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/contributors" class="contributor contributor_credentials contributorType">Deputy Editor</a><br><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/contributors" class="contributor contributor_credentials">Michael E Ross, MD</a><br></div>
					</div>
					
					 
					
								
				
				<div class="disc-over" id="disclosures">
				  	<div id="disclosures-scroller">
						
						
						<p><em><strong>Disclosures:</strong></em>
						
							<strong>Nasser Hanna, MD </strong>
							
						  	
						    	Nothing to disclose.
						    
						    
							
						
							<strong>Rogerio C Lilenbaum, MD, FACP </strong>
							
						  	
						    
								Consultant/Advisory Boards: Genentech [Lung Cancer (Bevacizumab)]; Boehringer-Ingelheim [Lung Cancer (Afatinib)].
							
							
						
							<strong>James R Jett, MD </strong>
							
						  	
						    
								Grant/Research/Clinical Trial Support: Oncimmune [lung cancer 
biomarkers (early CDT lung blood test)]; Metabolomx [biomarker lung 
cancer (breath and urine test in development)]. Consultant/Advisory 
Boards: Quest Diagnostics [lung cancer biomarkers (blood test in 
development)].
							
							
						
							<strong>Michael E Ross, MD </strong>
							
						  	
						    
								Employee of UpToDate, Inc.
							
							
						
						</p>
						
						<p class="contributorDisclosureInfo">
						Contributor disclosures are reviewed for conflicts of interest by 
the editorial group. When found, these are addressed by vetting through a
 
						multi-level review process, and through requirements for 
references to be provided to support the content. Appropriately 
referenced content is 
						required of all authors and must conform to UpToDate standards of 
evidence.
						</p>
						<p class="contributorDisclosurePolicy">
							<a href="http://www.uptodate.com/home/conflict-interest-policy" target="_blank">Conflict of interest policy</a>
						</p>
 					</div>
				</div>
				
			  
		 
		
		<div id="reviewProcess">
			<span>All topics are updated as new evidence becomes available and our <a href="http://www.uptodate.com/home/editorial-policy" target="_blank">peer review process</a> is complete.</span>
		</div>


		<div id="literatureReviewDate"> 
			<span class="emphasis">
				Literature review current through:
			</span>
			Jun 2014.
			<span class="pipeSpace">|</span>
			<span class="emphasis">
				This topic last updated:
			</span>
			Jun 23, 2014.
		</div>
		
		
		<!-- NEWER VERSION OF TOPIC MESSAGE -->
		
		
	
 


		<div id="topicText">
			<p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span>&nbsp;—&nbsp;Patients with stage I, II, or IIIA (<a href="http://www.uptodate.com/contents/image?imageKey=ONC%2F80099&amp;topicKey=ONC%2F4636&amp;source=see_link" class="graphic graphic_table graphicRef80099 ">table 1</a>)
 non-small cell lung cancer (NSCLC) are at substantial risk for 
recurrence and death even after complete surgical resection. 
Approximately 40 to 50 percent of patients with stage IB, 55 to 70 
percent of stage II, and a greater percentage of those with stage IIIA 
NSCLC eventually recur and die of their disease despite potentially 
curative surgery. (See <a href="http://www.uptodate.com/contents/tumor-node-metastasis-tnm-staging-system-for-non-small-cell-lung-cancer?source=see_link" class="medical medical_review">"Tumor node metastasis (TNM) staging system for non-small cell lung cancer"</a>.)</p><p>The
 development of active platinum-based combinations and the completion of
 large clinical trials assessing the activity of adjuvant chemotherapy 
for resected NSCLC have led to the use of adjuvant chemotherapy to 
improve the outcome in patients with completely resected NSCLC.</p><p>The
 results of the major adjuvant chemotherapy trials and their 
implications for the management of patients with completely resected 
NSCLC will be reviewed here. Other aspects of the initial treatment of 
patients with stages I, II, and III NSCLC are discussed separately. (See
 <a href="http://www.uptodate.com/contents/management-of-stage-i-and-stage-ii-non-small-cell-lung-cancer?source=see_link" class="medical medical_review">"Management of stage I and stage II non-small cell lung cancer"</a> and <a href="http://www.uptodate.com/contents/management-of-stage-iii-non-small-cell-lung-cancer?source=see_link" class="medical medical_review">"Management of stage III non-small cell lung cancer"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PROGNOSIS AFTER RESECTION</span>&nbsp;—&nbsp;A
 substantial proportion of patients with non-small cell lung cancer 
(NSCLC) who undergo an apparently complete resection eventually recur. 
Prognostic factors are useful in determining which patients may benefit 
from adjuvant chemotherapy.</p><p class="headingAnchor" id="H3"><span class="h2">Pathologic stage</span>&nbsp;—&nbsp;Pathologic (TNM) staging is the most important prognostic factor determining the likelihood of relapse.</p><p>The
 most extensive data correlating stage with prognosis come from a series
 of over 31,000 cases from the Surveillance, Epidemiology and End 
Results (SEER) database used to validate the 7th TNM staging system (<a href="http://www.uptodate.com/contents/image?imageKey=ONC%2F80099&amp;topicKey=ONC%2F4636&amp;source=see_link" class="graphic graphic_table graphicRef80099 ">table 1</a>) [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/1" class="abstract_t">1</a>].
 Survival decreased progressively with more advanced disease. For stages
 IA, IB, IIA, IIB, IIIA, and IIIB, the median survivals were 59, 48, 30,
 24, 14, and 9 months, respectively (<a href="http://www.uptodate.com/contents/image?imageKey=ONC%2F73088&amp;topicKey=ONC%2F4636&amp;source=see_link" class="graphic graphic_figure graphicRef73088 ">figure 1</a>). These data underscore the need for effective adjuvant therapy in all stages of resected NSCLC. (See <a href="http://www.uptodate.com/contents/overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-non-small-cell-lung-cancer?source=see_link" class="medical medical_review">"Overview of the initial evaluation, diagnosis, and staging of patients with suspected non-small cell lung cancer"</a> and <a href="http://www.uptodate.com/contents/tumor-node-metastasis-tnm-staging-system-for-non-small-cell-lung-cancer?source=see_link" class="medical medical_review">"Tumor node metastasis (TNM) staging system for non-small cell lung cancer"</a>.)</p><p>In
 the TNM staging system, the detection by immunohistochemistry of single
 tumor cells or small clusters of cells ≤0.2 mm in greatest dimension in
 lymph nodes is not sufficient for reclassification as pathologically 
positive. Such lymph nodes are classified as negative (pN0) [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/2" class="abstract_t">2</a>].
 However, the detection of such tumor cells is associated with a 
significantly poorer prognosis in patients with stage I NSCLC [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/3" class="abstract_t">3</a>].
 In a multicenter study that included over 1000 patients, occult nodal 
involvement was associated with poorer disease-free and overall survival
 rates compared with the absence of such occult metastases (hazard 
ratios 1.51, 95% CI 1.04-2.19, and 1.58, 95% CI 1.13-2.22, 
respectively).</p><p class="headingAnchor" id="H4"><span class="h2">Molecular markers</span>&nbsp;—&nbsp;Molecular
 markers may provide additional information about the likelihood of 
relapse beyond that obtained from pathologic staging.</p><p>Approaches and specific markers under study include gene expression profiling, ERCC 1 expression, abnormalities in the <em>k-ras</em>
 oncogene and p53 tumor suppressor gene, and DNA methylation markers. 
Additional studies will be required to determine whether these markers 
are useful in selecting patients for adjuvant platinum-based 
chemotherapy.</p><p class="headingAnchor" id="H5"><span class="h3">Gene expression profiling</span>&nbsp;—&nbsp;Gene
 expression profiles are being developed that may be useful in defining 
favorable and unfavorable prognostic subsets [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/4-7" class="abstract_t">4-7</a>].
 Results with these gene expression profiles have the potential to 
divide patients with stage I disease into different risk groups, and 
thus identify those who might benefit from adjuvant chemotherapy. </p><p>As
 an example, a 14-gene expression profile was developed in a cohort of 
361 patients who had non-squamous NSCLC resected at a single institution
 [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/7" class="abstract_t">7</a>].
 This profile used quantitative polymerase chain reaction (PCR) and was 
run on paraffin embedded tumor tissue. This profile was then validated 
in two other cohorts, one with 433 patients who had undergone resection 
for stage I non-squamous NSCLC and the other in 1006 patients who had 
undergone resection of stages I, II, or III non-squamous NSCLC. In all 
three cohorts, approximately 80 to 90 percent of patients had 
adenocarcinoma. When the original criteria were applied to the 
validation cohorts, the five year survival rates in the low-risk, 
intermediate-risk, and high-risk patients were 71, 58, and 49 percent, 
respectively. These differences could not be explained on the basis of 
other known prognostic factors.</p><p class="headingAnchor" id="H7"><span class="h3">k-ras and p53</span>&nbsp;—&nbsp;Both the k-ras oncogene and the p53 tumor suppressor gene have been implicated in the pathogenesis of NSCLC. </p><p>Abnormalities in these genes were studied in a subset of 253 patients from the JBR 10 adjuvant chemotherapy trial [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/8" class="abstract_t">8</a>]. (See <a href="#H14" class="local">'JBR 10'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>Patients
 with mutations in k-ras in their tumor did not appear to benefit from 
adjuvant chemotherapy, while those with wild-type k-ras did 
significantly better.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Overexpression
 of the p53 gene as assessed by immunohistochemistry was associated with
 a significantly poorer prognosis compared to those who were negative 
for p53 overexpression, but the benefit from adjuvant chemotherapy was 
greater among those with p53 overexpression. Patients with mutations in 
p53 did not appear to benefit from adjuvant chemotherapy.</p><p></p><p>Similarly,
 in an analysis of biomarkers from 1532 patients in the LACE-bio study, 
patients with a mutation in k-ras codon 13 had significantly poorer 
outcomes when treated with adjuvant chemotherapy compared to those 
without a codon 13 mutation [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/9" class="abstract_t">9</a>].</p><p class="headingAnchor" id="H8"><span class="h3">DNA methylation markers</span>&nbsp;—&nbsp;Methylation
 of the promoter region of four genes thought to be important in the 
pathogenesis of lung cancer (p16, CDH13, APC, and RASSF1A) has been 
associated with a significantly increased risk of recurrent NSCLC [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/10" class="abstract_t">10</a>].
 In a study of 167 patients who underwent potentially curative resection
 of stage I NSCLC, including 51 who relapsed within 40 months after 
surgery, the absence of promoter methylation correlated with higher 
rates of subsequent recurrence-free survival (77, 51, and 30 percent at 
five years in those with none, one or two, and three or four methylated 
genes, respectively).</p><p>As with other molecular markers, these 
results require confirmation in a larger prospective study before they 
can be used to select patients for adjuvant therapy.</p><p class="headingAnchor" id="H9"><span class="h1">ADJUVANT CHEMOTHERAPY</span>&nbsp;—&nbsp;Adjuvant
 platinum-based chemotherapy is generally recommended for patients with 
stage II and III NSCLC following potentially curative surgery, and may 
also have a role in the treatment of some patients with stage IB disease
 (<a href="http://www.uptodate.com/contents/image?imageKey=ONC%2F80099&amp;topicKey=ONC%2F4636&amp;source=see_link" class="graphic graphic_table graphicRef80099 ">table 1</a>). Adjuvant chemotherapy is not indicated for patients with resected stage IA disease.</p><p class="headingAnchor" id="H10"><span class="h2">Early clinical trials</span>&nbsp;—&nbsp;During
 the 1970s and early 1980s, a number of clinical trials evaluated 
whether adjuvant chemotherapy improved survival following presumed 
complete surgical resection. These trials did not provide consistent 
evidence of benefit, and adjuvant chemotherapy was not widely used. 
Furthermore, adjuvant chemotherapy was poorly tolerated during this era,
 as optimal supportive measures, such as effective antiemetics, were not
 available.</p><p>A 1995 meta-analysis that included data on 4357 
patients from 14 randomized trials failed to demonstrate a survival 
advantage for adjuvant chemotherapy [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/11" class="abstract_t">11</a>]. However, a subset analysis of trials using <a href="http://www.uptodate.com/contents/cisplatin-drug-information?source=see_link" class="drug drug_general">cisplatin</a>-based regimens suggested a survival benefit, although the difference was not statistically significant.</p><p>Key findings from this meta-analysis included the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In
 five trials utilizing alkylator-based regimens, patients treated with 
surgery alone had a survival advantage, and the risk of death was 15 
percent higher among those randomized to adjuvant chemotherapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the eight trials that utilized a <a href="http://www.uptodate.com/contents/cisplatin-drug-information?source=see_link" class="drug drug_general">cisplatin</a>-based
 chemotherapy regimen, adjuvant chemotherapy was associated with a 13 
percent reduction in the risk of death, which translated into a 5 
percent absolute improvement in the likelihood of surviving five years, 
which did not reach statistical significance.</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Platinum-based chemotherapy</span>&nbsp;—&nbsp;Subsequently,
 multiple large trials utilized platinum-based combinations as an 
adjuvant following complete surgical resection of NSCLC (<a href="http://www.uptodate.com/contents/image?imageKey=ONC%2F90104&amp;topicKey=ONC%2F4636&amp;source=see_link" class="graphic graphic_table graphicRef90104 ">table 2</a>) [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/12-18" class="abstract_t">12-18</a>].
 Sufficient data are now available from these trials and from a 
meta-analysis of these newer trials to conclude that adjuvant 
chemotherapy is useful for patients with completely resected NSCLC stage
 II and IIIA NSCLC. The data for patients with resected stage IB disease
 are less conclusive. </p><p>The results of the LACE meta-analysis as well as results from the larger, homogeneous trials are discussed here.</p><p class="headingAnchor" id="H12"><span class="h3">LACE meta-analysis</span>&nbsp;—&nbsp;The improved survival with adjuvant chemotherapy using modern drug regimens was confirmed in the Lung Adjuvant <a href="http://www.uptodate.com/contents/cisplatin-drug-information?source=see_link" class="drug drug_general">Cisplatin</a> Evaluation (LACE) meta-analysis that combined individual patient data from the five largest trials [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/12-16,19" class="abstract_t">12-16,19</a>].</p><p>All five trials used <a href="http://www.uptodate.com/contents/cisplatin-drug-information?source=see_link" class="drug drug_general">cisplatin</a>-based chemotherapy, although the IALT [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/12" class="abstract_t">12</a>], European Big Lung [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/13" class="abstract_t">13</a>] and the Adjuvant Lung Project Italy (ALPI) [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/14" class="abstract_t">14</a>]
 trials each integrated cisplatin into multiple chemotherapy regimens. 
In addition, these three trials allowed the use of adjuvant thoracic 
radiation at the discretion of the treating clinician, as did the ANITA 
trial [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/15" class="abstract_t">15</a>].
 The two homogenous trials included in this meta-analysis (ANITA and JBR
 10), along with IALT, the largest trial, are discussed below.</p><p>In a
 pooled analysis of 4584 patients with a median follow-up of 5.2 years, 
adjuvant chemotherapy was associated with a decreased risk of death of 
5.4 percent at five years compared to no chemotherapy (hazard ratio [HR]
 0.89, 95% CI 0.82-0.96) [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/19" class="abstract_t">19</a>].
 The survival benefit varied according to stage and was most pronounced 
for patients with stage II and IIIA disease. The improvement in survival
 in patients with stage IB disease did not reach statistical 
significance, and patients with stage IA disease did worse with adjuvant
 chemotherapy:</p><p class="bulletIndent1"><span class="glyph">●</span>Stage IA — HR 1.40 (95% CI 0.95-2.06)</p><p class="bulletIndent1"><span class="glyph">●</span>Stage IB — HR 0.93 (95% CI 0.78-1.10)</p><p class="bulletIndent1"><span class="glyph">●</span>Stage II — HR 0.83 (95% CI 0.73-0.95)</p><p class="bulletIndent1"><span class="glyph">●</span>Stage III — HR 0.83 (95% CI 0.72-0.94)</p><p></p><p>A
 subsequent meta-analysis that included individual patient data from 
these and older trials confirmed the survival benefit seen in the LACE 
meta-analysis [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/20" class="abstract_t">20</a>].
 This meta-analysis provided additional support for the role of adjuvant
 chemotherapy in patients with stage IB disease. In addition, that 
analysis provided evidence that adjuvant chemotherapy had similar 
efficacy in patients whose initial treatment included both surgery and 
radiation therapy.</p><p>The various trials on adjuvant chemotherapy 
have not specifically analyzed patients with stage II disease based upon
 the presence of multiple tumors within the same lobe of the lung (T3N0 
disease). Thus, these patients are generally treated in the same manner 
as other patients with stage II disease.</p><p class="headingAnchor" id="H13"><span class="h3">ANITA</span>&nbsp;—&nbsp;In
 the ANITA trial, 799 evaluable patients with stage IB, II, or IIIA 
NSCLC (36, 24, and 39 percent, respectively) were randomly assigned to 
four cycles of <a href="http://www.uptodate.com/contents/vinorelbine-drug-information?source=see_link" class="drug drug_general">vinorelbine</a> (30 <span class="nowrap">mg/m2</span> per week for 16 weeks) plus <a href="http://www.uptodate.com/contents/cisplatin-drug-information?source=see_link" class="drug drug_general">cisplatin</a> (100 <span class="nowrap">mg/m2</span> on day 1 every four weeks) or observation [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/15" class="abstract_t">15</a>].
 Postoperative radiation therapy (RT) was optional and determined by the
 centers prior to patient enrollment. RT was administered to 24 percent 
of chemotherapy patients and 33 percent of those assigned to 
observation.</p><p>At a median follow-up of 76 months, survival was 
significantly increased with chemotherapy (median 66 versus 44 months 
with observation). The absolute overall survival benefit with adjuvant 
chemotherapy was 8.6 percent at five years and 8.4 percent at seven 
years. The survival benefit appeared to be mainly in patients with stage
 II and IIIA disease.</p><p>Toxicity associated with <a href="http://www.uptodate.com/contents/vinorelbine-drug-information?source=see_link" class="drug drug_general">vinorelbine</a> and <a href="http://www.uptodate.com/contents/cisplatin-drug-information?source=see_link" class="drug drug_general">cisplatin</a>
 was manageable. Grade 3 or 4 neutropenia, febrile neutropenia, nausea 
and vomiting, constipation and peripheral neuropathy were observed in 
85, 9, 27, 5, and 3 percent of patients, respectively. There were seven 
chemotherapy-related deaths (2 percent).</p><p class="headingAnchor" id="H14"><span class="h3">JBR 10</span>&nbsp;—&nbsp;A
 similar degree of benefit for adjuvant chemotherapy was reported in the
 intergroup JBR 10 trial, in which 482 patients with completely resected
 stage IB or II (excluding T3N0) NSCLC were randomly assigned to surgery
 followed by four cycles of <a href="http://www.uptodate.com/contents/vinorelbine-drug-information?source=see_link" class="drug drug_general">vinorelbine</a> (25 <span class="nowrap">mg/m2</span> weekly for 16 weeks) plus <a href="http://www.uptodate.com/contents/cisplatin-drug-information?source=see_link" class="drug drug_general">cisplatin</a> (50 <span class="nowrap">mg/m2</span> days 1 and 8, every four weeks) or surgery alone [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/16" class="abstract_t">16</a>].</p><p>The outcomes from this trial were updated with a median follow-up of over nine years [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/21" class="abstract_t">21</a>]. Findings included:</p><p class="bulletIndent1"><span class="glyph">●</span>The
 five-year overall survival rate was significantly increased with 
adjuvant chemotherapy compared to observation (67 versus 56 percent, 
hazard ratio 0.78).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with stage II disease had a significant improvement in five-year overall survival (59 versus 44 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The
 outcome in patients with stage I NSCLC depended upon the size of the 
tumor. Overall, there was no benefit (five-year survival 76 versus 69 
percent, HR 1.03). In those with a primary tumor &lt;4 cm, chemotherapy 
was associated with a poorer outcome (73 versus 79 percent, HR 1.73), 
while for those with a primary tumor ≥4 cm, chemotherapy improved 
survival (79 versus 59 percent, HR 0.68). These findings regarding the 
impact of primary tumor size are consistent with the CALGB 9633 trial. 
(See <a href="#H16" class="local">'CALGB 9633'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There
 was no evidence that adjuvant chemotherapy was associated with an 
excess of deaths from other causes or secondary malignancies.</p><p></p><p>The
 most common toxicity was hematologic (grade 3 or 4 neutropenia in 73 
percent of patients, febrile neutropenia in 7 percent). There were two 
treatment-related deaths (one each from pulmonary fibrosis and febrile 
neutropenia). The most frequent non-hematologic grade 3 or 4 toxicities 
included fatigue (15 percent), anorexia (10 percent), and vomiting (10 
percent).</p><p>The impact of adjuvant chemotherapy on quality of life 
(QOL) was assessed in a subset of 359 patients from this trial who 
completed a baseline assessment [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/22" class="abstract_t">22</a>].
 Patients receiving adjuvant chemotherapy had transient worsening in QOL
 due to fatigue, nausea, and vomiting. However, the QOL of patients 
treated with chemotherapy returned to baseline by nine months, except 
for symptoms of sensory neuropathy and hearing loss.</p><p>Similarly, an
 analysis of all 482 patients looking at the quality-adjusted time 
without symptoms or toxicity found that adjuvant chemotherapy improved 
quality-adjusted survival despite the toxicity associated with 
chemotherapy [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/23" class="abstract_t">23</a>].</p><p>The results of this trial in the subset of older patients are discussed below. (See <a href="#H17" class="local">'Elderly patients'</a> below.)</p><p class="headingAnchor" id="H15"><span class="h3">IALT</span>&nbsp;—&nbsp;The
 largest, platinum-based experience with adjuvant chemotherapy comes 
from the International Adjuvant Lung Cancer Trial (IALT), in which 1867 
patients with resected stage I, II, or III NSCLC were randomly assigned 
to three or four cycles of <a href="http://www.uptodate.com/contents/cisplatin-drug-information?source=see_link" class="drug drug_general">cisplatin</a>-based chemotherapy or to observation [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/12,24" class="abstract_t">12,24</a>].
 At a median follow-up of 56 months, the five-year survival rate was 
higher with adjuvant chemotherapy (44.5 versus 40.4 percent, hazard 
ratio [HR] 0.86, 95% CI 0.76-0.98). </p><p>In a subsequent report with 
median follow-up of 7.5 years, adjuvant chemotherapy was associated with
 a significant improvement in disease-free survival (HR 0.88, 95% CI 
0.78-0.98) and a trend toward improved overall survival (hazard ratio 
[HR] 0.91, 95% CI 0.81-1.02, p = 0.10) [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/24" class="abstract_t">24</a>].
 There was a trend toward an increase in non-lung cancer deaths over the
 entire observation period (HR 1.34, 95% CI 0.99-1.81, p = 0.06).</p><p class="headingAnchor" id="H16"><span class="h3">CALGB 9633</span>&nbsp;—&nbsp;Cancer and Leukemia Group B (CALGB) 9633 is the only large adjuvant chemotherapy trial utilizing <a href="http://www.uptodate.com/contents/carboplatin-drug-information?source=see_link" class="drug drug_general">carboplatin</a> rather than <a href="http://www.uptodate.com/contents/cisplatin-drug-information?source=see_link" class="drug drug_general">cisplatin</a> [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/17,18" class="abstract_t">17,18</a>]. In this trial, 344 patients with completely resected stage IB NSCLC were randomly assigned to four cycles of adjuvant <a href="http://www.uptodate.com/contents/paclitaxel-drug-information?source=see_link" class="drug drug_general">paclitaxel</a> (200 <span class="nowrap">mg/m2</span>
 over three hours every three weeks) plus carboplatin (area under the 
concentration x time curve [AUC] 6 every three weeks) or observation.</p><p>In
 a preliminary report presented at the American Society of Clinical 
Oncology (ASCO) meeting in 2004, treatment with adjuvant chemotherapy 
was associated with significant improvements in overall and disease-free
 survival [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/17" class="abstract_t">17</a>].
 At a median follow-up of 34 months, adjuvant chemotherapy was 
associated with a 38 percent reduction in the risk of death (HR=0.62; 
95%CI 0.41-0.95). There was a 12 percent improvement in four-year 
overall survival rate (71 versus 59 percent). In accordance with the 
statistical plan, the trial was stopped early after the planned interim 
analysis demonstrated a significant improvement in overall survival. 
Treatment was well tolerated overall, and there were no 
treatment-related deaths.</p><p>However, at a median follow-up of 74 
months, the difference in survival was no longer statistically 
significant (HR 0.83, 95% CI 0.64-1.08) [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/18" class="abstract_t">18</a>].
 In an exploratory subset analysis, there was a statistically 
significant survival advantage for patients whose tumors were greater 
than or equal to 4 cm (HR 0.69, 95% CI 0.48-0.99). The relatively small 
size of the study and its premature closure may have contributed to this
 outcome. The study was limited to patients with stage IB disease, a 
population that did not benefit in other trials. Furthermore, the use of
 <a href="http://www.uptodate.com/contents/carboplatin-drug-information?source=see_link" class="drug drug_general">carboplatin</a>, rather than <a href="http://www.uptodate.com/contents/cisplatin-drug-information?source=see_link" class="drug drug_general">cisplatin</a>, may have affected the efficacy of adjuvant chemotherapy in this patient population. (See <a href="http://www.uptodate.com/contents/systemic-therapy-for-the-initial-management-of-advanced-non-small-cell-lung-cancer-without-a-driver-mutation?source=see_link&amp;anchor=H9#H9" class="medical medical_review">"Systemic
 therapy for the initial management of advanced non-small cell lung 
cancer without a driver mutation", section on 'Cisplatin versus 
carboplatin'</a>.) </p><p class="headingAnchor" id="H632650843"><span class="h2">Stage IB disease</span>&nbsp;—&nbsp;The
 role of adjuvant chemotherapy for patients with resected stage IB 
disease remains controversial, and there is no consensus regarding which
 patients might be candidates for adjuvant therapy.</p><p>The LACE meta-analysis showed a nonsignificant trend toward improved overall survival [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/19" class="abstract_t">19</a>].
 Subsequent studies have attempted to define which of these patients 
might fall into a high-risk subset. Factors that have been studied 
include the size of the resected primary tumor, the presence or absence 
of lymphovascular invasion, histology (poorly versus well 
differentiated), or the level of activity seen on PET.</p><p class="headingAnchor" id="H17"><span class="h2">Elderly patients</span>&nbsp;—&nbsp;The
 available data suggest that older adults with resected NSCLC should not
 be excluded from receiving adjuvant chemotherapy based upon age. The 
decision to pursue such therapy should consider both the potential 
benefits of such treatment and the health of the individual patient. </p><p>The
 role of adjuvant chemotherapy in appropriately selected elderly 
patients is supported by both the LACE meta-analysis and unplanned 
subset analysis of the JBR 10 trial (which was one of the trials 
included in the meta-analysis) [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/25,26" class="abstract_t">25,26</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>The
 LACE meta-analysis also found that efficacy was not significantly 
different in elderly compared to younger patients, even though older 
patients received lower doses and fewer cycles of chemotherapy [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/25" class="abstract_t">25</a>]. In addition, no differences in severe toxicity were observed. (See <a href="#H12" class="local">'LACE meta-analysis'</a> above.) &nbsp;</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The
 increased difficulty in administering chemotherapy in older patients is
 illustrated by the subset analysis of JBR 10, in which 32 percent were 
more than 65 years of age [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/26" class="abstract_t">26</a>].
 The older patients received fewer cycles of chemotherapy (median three 
versus four cycles in those ≤65 years). Despite this, adjuvant 
chemotherapy was associated with a survival benefit in those &gt;65 
years that was similar to that in younger patients. (See <a href="#H14" class="local">'JBR 10'</a> above.)</p><p></p><p>Neither
 of these analyses can be generalized to assess the role of adjuvant 
chemotherapy in the broader population of older patients, since those 
enrolled in these adjuvant chemotherapy trials represent a group that is
 probably substantially different than those of similar age who were not
 enrolled and may even be more fit than some of the younger patients 
entered into the protocol. </p><p>Elderly patients have not been well 
represented in adjuvant trials. In the randomized trials, the median age
 of patients was relatively young, patients over age 75 years were 
excluded from two trials, and less than 10 percent of patients in the 
LACE meta-analysis were over 75 years. As a result, recommendations must
 be made on an individual basis. </p><p>Special considerations for the use of chemotherapy in elderly patients are discussed separately. (See <a href="http://www.uptodate.com/contents/comprehensive-geriatric-assessment-for-patients-with-cancer?source=see_link" class="medical medical_review">"Comprehensive geriatric assessment for patients with cancer"</a> and <a href="http://www.uptodate.com/contents/systemic-chemotherapy-for-cancer-in-elderly-persons?source=see_link" class="medical medical_review">"Systemic chemotherapy for cancer in elderly persons"</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">ASCO and NCCN guidelines</span>&nbsp;—&nbsp;Guidelines from the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/27" class="abstract_t">27</a>] and from the National Comprehensive Cancer Network (NCCN) [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/28" class="abstract_t">28</a>] recommend adjuvant systemic chemotherapy with a <a href="http://www.uptodate.com/contents/cisplatin-drug-information?source=see_link" class="drug drug_general">cisplatin</a>-based regimen for patients with completely resected stage II or IIIA NSCLC.</p><p>For
 patients with stage IB NSCLC, the ASCO Cancer Care Ontario guidelines 
do not endorse adjuvant chemotherapy for routine use because of the lack
 of definitive evidence establishing improved survival. The NCCN 
guidelines consider either observation or adjuvant chemotherapy 
appropriate options for patients with resected stage IB NSCLC depending 
on risk factors for recurrence.</p><p class="headingAnchor" id="H13804081"><span class="h2">Choice of chemotherapy regimen</span>&nbsp;—&nbsp;There
 are no randomized clinical trials that compare different platinum-based
 chemotherapy regimens in the adjuvant setting, and the data from the 
LACE meta-analysis were inadequate to establish the optimal <a href="http://www.uptodate.com/contents/cisplatin-drug-information?source=see_link" class="drug drug_general">cisplatin</a> regimen [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/19" class="abstract_t">19</a>]. </p><p>Guidelines from the NCCN recommend the use of a <a href="http://www.uptodate.com/contents/cisplatin-drug-information?source=see_link" class="drug drug_general">cisplatin</a>-based doublet with a third generation cytotoxic agent [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/28" class="abstract_t">28</a>]. The use of <a href="http://www.uptodate.com/contents/pemetrexed-drug-information?source=see_link" class="drug drug_general">pemetrexed</a>
 in combination with cisplatin should be restricted to patients with 
non-squamous histology. Various cisplatin chemotherapy regimens are 
presented separately. (See <a href="http://www.uptodate.com/contents/treatment-protocols-for-non-small-cell-lung-cancer?source=see_link" class="medical medical_review">"Treatment protocols for non-small cell lung cancer"</a>.)</p><p class="headingAnchor" id="H1604110"><span class="h1">MOLECULARLY TARGETED AGENTS</span>&nbsp;—&nbsp;Despite
 the activity of tyrosine kinase inhibitors in patients with metastatic 
non-small cell lung cancer (NSCLC) that contains either a mutation in 
the epidermal growth factor receptor (EGFR) or the ALK fusion oncogene, 
there is no indication for the use of targeted agents as an adjuvant 
outside of a clinical trial setting. (See <a href="http://www.uptodate.com/contents/systemic-therapy-for-advanced-non-small-cell-lung-cancer-with-an-activating-mutation-in-the-epidermal-growth-factor-receptor?source=see_link" class="medical medical_review">"Systemic therapy for advanced non-small cell lung cancer with an activating mutation in the epidermal growth factor receptor"</a>.) </p><p>In
 two trials with patients not selected based upon EGFR mutation status, 
adjuvant EGFR tyrosine kinase inhibitors do not improve survival:</p><p class="bulletIndent1"><span class="glyph">●</span>In a multicenter, placebo controlled trial, 503 patients were randomly assigned to <a href="http://www.uptodate.com/contents/gefitinib-drug-information?source=see_link" class="drug drug_general">gefitinib</a> or placebo between 2002 and 2005 [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/29" class="abstract_t">29</a>].
 All patients had completely resected NSCLC; patients were stratified 
based upon whether or not they received adjuvant chemotherapy, which was
 given in 15 percent of cases. </p><p></p><p class="bulletIndent1">In 
the final analysis with a minimum follow-up of four years, there was a 
trend toward better overall and disease-free survival in patients 
assigned to placebo (HR1.24, 95% CI 0.94-1.64 and HR 1.22, 95% CI 
0.93-1.61, respectively). No benefit was observed in subset analyses 
based upon EGFR mutation status. However, these results must be 
interpreted with caution, since only 15 of 359 patients (4 percent) were
 positive for EGFR. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In
 the RADIANT trial, 973 patients were randomly assigned to two years of 
treatment after complete surgical resection for stage I, II, or IIIA 
NSCLC [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/30,31" class="abstract_t">30,31</a>].
 All patients had increased EGFR expression, either by 
immunohistochemistry or by fluorescence in situ hybridization (FISH). 
Approximately one-half of patients had received adjuvant chemotherapy 
prior to randomization. </p><p></p><p class="bulletIndent1">There was no
 statistically significant difference in disease-free survival, the 
primary endpoint of the trial (median 50 versus 48 months, HR 0.90, HR 
0.90, 95% CI 0.74-1.10).</p><p></p><p>The potential role of adjuvant 
EGFR tyrosine kinase inhibitors in patients with completely resected 
NSCLC that contains a sensitizing mutation in EGFR remains uncertain:</p><p class="bulletIndent1"><span class="glyph">●</span>Observational
 data from a single center database of 286 mutation positive patients 
found a trend toward improved survival in the 84 patients who received 
adjuvant <a href="http://www.uptodate.com/contents/erlotinib-drug-information?source=see_link" class="drug drug_general">erlotinib</a> or <a href="http://www.uptodate.com/contents/gefitinib-drug-information?source=see_link" class="drug drug_general">gefitinib</a> (HR 0.50, 95%CI 0.23-1.08, p = 0.076) [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/32" class="abstract_t">32</a>].
 Interpretation of these results is particularly difficult since 45 
percent of the patients receiving adjuvant erlotinib or gefitinib had 
received adjuvant cytotoxic chemotherapy as well. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the RADIANT trial, 161 of the 973 patients (17 percent) had either an exon 19 deletion or an L858R mutation [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/30,31" class="abstract_t">30,31</a>].
 For these patients, the disease-free survival was increased (median 46 
versus 28 months, HR 0.61, 95% CI 0.38-0.98); these results were not 
statistically significant given the hierarchical statistical design of 
the trial. There was no evidence of improvement in overall survival 
(medians not reached, HR 1.09). However, only 35 of 161 (22 percent) of 
participants with an EGFR mutation had died at the time of analysis [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/30" class="abstract_t">30</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The multicenter phase II SELECT trial is studying adjuvant <a href="http://www.uptodate.com/contents/erlotinib-drug-information?source=see_link" class="drug drug_general">erlotinib</a> in 100 patients with resected, state IA to IIIA EGFR mutation positive NSCLC who have undergone adjuvant chemotherapy <span class="nowrap">and/or</span> radiation therapy [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/33" class="abstract_t">33</a>].
 Preliminary results presented at the 2014 ASCO meeting indicate that 
adjuvant erlotinib can improve disease-free survival compared with 
historical controls. Only 2 of 22 recurrences occurred while on adjuvant
 chemotherapy. Median time to recurrence was 12 months after stopping 
the erlotinib. </p><p></p><p>A phase III trial of adjuvant <a href="http://www.uptodate.com/contents/erlotinib-drug-information?source=see_link" class="drug drug_general">erlotinib</a> in resected patients with an EGFR mutation is being planned.</p><p class="headingAnchor" id="H20"><span class="h1">NEOADJUVANT CHEMOTHERAPY</span>&nbsp;—&nbsp;Although
 neoadjuvant chemotherapy prior to surgery for patients with resectable 
non-small cell lung cancer (NSCLC) has been studied extensively in 
randomized clinical trials, immediate surgery followed by postoperative 
adjuvant chemotherapy has largely replaced this approach. Surgery 
followed by adjuvant chemotherapy offers at least an equivalent benefit 
in terms of survival compared with neoadjuvant chemotherapy followed by 
surgery, and permits more accurate staging of disease, which may 
substantially alter the approach to patient management.</p><p>A 
systematic review of the literature and meta-analysis analyzed 
individual patient data from 2385 cases in 15 randomized trials 
comparing neoadjuvant chemotherapy followed by surgery with surgery 
alone [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/34" class="abstract_t">34</a>].
 The trials accrued patients between 1985 and 2007, and all but one 
utilized a platinum-based chemotherapy regimen; most patients had 
clinical stage IB to IIIA disease.</p><p>The primary endpoint for the 
meta-analysis was overall survival. There was a statistically 
significant improvement with neoadjuvant chemotherapy, measured from 
randomization (five-year survival rate 45 versus 40 percent, hazard 
ratio [HR] 0.87, 95% CI 0.78-0.96). Secondary endpoints of 
recurrence-free survival and distant metastasis-free survival both 
significantly favored preoperative chemotherapy; there was a trend for 
decreased risk of locoregional recurrence, but that was not 
statistically significant.</p><p>Analyses based upon stage of disease, 
chemotherapy regimen, the possible role of postoperative radiation 
therapy (RT), or other patient characteristics did not define any groups
 for which neoadjuvant chemotherapy was either more or less beneficial. 
There was no significant heterogeneity between the clinical trials.</p><p>The
 neoadjuvant approach remains a standard option for potentially 
resectable stage IIIA disease. This approach may have particular utility
 in the patient with single station, N2 lymph node involvement. The 
management of patients with clinical stage III NSCLC is discussed in 
detail separately. (See <a href="http://www.uptodate.com/contents/management-of-stage-iii-non-small-cell-lung-cancer?source=see_link" class="medical medical_review">"Management of stage III non-small cell lung cancer"</a>.)</p><p class="headingAnchor" id="PATIENT_INFORMATION"><span class="h1">INFORMATION FOR PATIENTS</span>&nbsp;—&nbsp;UpToDate
 offers two types of patient education materials, “The Basics” and 
“Beyond the Basics.” The Basics patient education pieces are written in 
plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading 
level, and they answer the four or five key questions a patient might 
have about a given condition. These articles are best for patients who 
want a general overview and who prefer short, easy-to-read materials. 
Beyond the Basics patient education pieces are longer, more 
sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here
 are the patient education articles that are relevant to this topic. We 
encourage you to print or e-mail these topics to your patients. (You can
 also locate patient education articles on a variety of subjects by 
searching on “patient info” and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see <a href="http://www.uptodate.com/contents/non-small-cell-lung-cancer-the-basics?source=see_link" class="medical medical_basics">"Patient information: Non-small cell lung cancer (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see <a href="http://www.uptodate.com/contents/non-small-cell-lung-cancer-treatment-stage-i-to-iii-cancer-beyond-the-basics?source=see_link" class="medical medical_patient">"Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)"</a> and <a href="http://www.uptodate.com/contents/non-small-cell-lung-cancer-treatment-stage-iv-cancer-beyond-the-basics?source=see_link" class="medical medical_patient">"Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span>&nbsp;—&nbsp;Multiple large randomized trials have demonstrated that adjuvant chemotherapy using modern <a href="http://www.uptodate.com/contents/cisplatin-drug-information?source=see_link" class="drug drug_general">cisplatin</a>-based
 regimens can significantly improve five-year survival in carefully 
selected patients with non-small cell lung cancer (NSCLC). These 
benefits have been confirmed in a meta-analysis of trials based upon 
individual patient data using modern chemotherapy regimens. The survival
 advantage is most pronounced for those with stage II and IIIA disease, 
but some patients with stage IB may benefit as well. (See <a href="#H11" class="local">'Platinum-based chemotherapy'</a> above and <a href="#H12" class="local">'LACE meta-analysis'</a> above.)</p><p>A web-based tool is available (<a href="http://www.adjuvantonline.com/index.jsp" class="external">Adjuvant! Online for lung cancer</a>)
 to aid the clinician in calculating the relative risk of disease 
recurrence and mortality based upon clinicopathologic features and the 
relative benefit to be gained by adjuvant chemotherapy [<a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/35" class="abstract_t">35</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>For
 patients with stage II and IIIA NSCLC who are willing and able to 
tolerate adjuvant chemotherapy, we recommend treatment with a <a href="http://www.uptodate.com/contents/cisplatin-drug-information?source=see_link" class="drug drug_general">cisplatin</a>-based doublet (<a href="http://www.uptodate.com/contents/grade/1?title=Grade%201A&amp;topicKey=ONC/4636" class="grade">Grade 1A</a>). (See <a href="#H11" class="local">'Platinum-based chemotherapy'</a> above and <a href="http://www.uptodate.com/contents/treatment-protocols-for-non-small-cell-lung-cancer?source=see_link" class="medical medical_review">"Treatment protocols for non-small cell lung cancer"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The optimal chemotherapy regimen has not been determined in randomized trials. The use of <a href="http://www.uptodate.com/contents/cisplatin-drug-information?source=see_link" class="drug drug_general">cisplatin</a> plus <a href="http://www.uptodate.com/contents/pemetrexed-drug-information?source=see_link" class="drug drug_general">pemetrexed</a> should be restricted to patients with non-squamous histology. (See <a href="#H13804081" class="local">'Choice of chemotherapy regimen'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The use of <a href="http://www.uptodate.com/contents/carboplatin-drug-information?source=see_link" class="drug drug_general">carboplatin</a> based regimens (eg, carboplatin plus <a href="http://www.uptodate.com/contents/paclitaxel-drug-information?source=see_link" class="drug drug_general">paclitaxel</a>) should be limited to patients with significant comorbidity and those who cannot tolerate a <a href="http://www.uptodate.com/contents/cisplatin-drug-information?source=see_link" class="drug drug_general">cisplatin</a>-based regimen. (See <a href="#H16" class="local">'CALGB 9633'</a> above.)”</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with stage IB NSCLC who are able to tolerate adjuvant chemotherapy, we suggest adjuvant therapy with a <a href="http://www.uptodate.com/contents/cisplatin-drug-information?source=see_link" class="drug drug_general">cisplatin</a>-based doublet rather than no adjuvant chemotherapy (<a href="http://www.uptodate.com/contents/grade/5?title=Grade%202B&amp;topicKey=ONC/4636" class="grade">Grade 2B</a>). Patients may reasonably choose to not have adjuvant chemotherapy.(See <a href="#H12" class="local">'LACE meta-analysis'</a> above and <a href="#H11" class="local">'Platinum-based chemotherapy'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For
 patients with resected stage IA NSCLC, we recommend not using adjuvant 
chemotherapy except in the context of a clinical trial because of the 
favorable prognosis and absence of data supporting a benefit (<a href="http://www.uptodate.com/contents/grade/1?title=Grade%201A&amp;topicKey=ONC/4636" class="grade">Grade 1A</a>). (See <a href="#H12" class="local">'LACE meta-analysis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For
 carefully selected older patients with resected stages IB, II, and IIIA
 NSCLC, we suggest adjuvant chemotherapy using the same chemotherapy 
regimens as for younger patients (<a href="http://www.uptodate.com/contents/grade/5?title=Grade%202B&amp;topicKey=ONC/4636" class="grade">Grade 2B</a>).
 The decision of whether or not to use adjuvant chemotherapy in elderly 
adults must be individualized. A comprehensive geriatric analysis may be
 useful prior to making a decision about whether or not to proceed with 
adjuvant chemotherapy. In an exploratory analysis of the CALGB 9633 
trial, there was a statistically significant survival advantage for 
patients whose tumors were greater than or equal to 4 cm, but not for 
those with smaller lesions. (See <a href="#H17" class="local">'Elderly patients'</a> above and <a href="http://www.uptodate.com/contents/comprehensive-geriatric-assessment-for-patients-with-cancer?source=see_link" class="medical medical_review">"Comprehensive geriatric assessment for patients with cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although
 data from multiple clinical trials suggest that neoadjuvant 
chemotherapy prior to surgery is associated with an overall survival 
benefit, this approach relies upon clinical staging, which has been 
associated with a significant risk of under or overestimating the stage 
of disease. Although neoadjuvant chemotherapy has largely been replaced 
by adjuvant chemotherapy in appropriate candidates, neoadjuvant 
chemotherapy is an option in patients with potentially resectable, stage
 IIIA disease. (See <a href="#H20" class="local">'Neoadjuvant chemotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There
 are no data to support the use of targeted therapy outside of a 
clinical trial for patients whose primary tumor contains a mutation in 
EGFR or the ALK fusion oncogene. (See <a href="#H1604110" class="local">'Molecularly targeted agents'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Whenever possible, patients should be encouraged to participate in clinical trials.</p><p>
		</p></div>
		
		












<div id="topicAgreement">
	Use of UpToDate is subject to the <a href="http://www.uptodate.com/contents/license" target="_blank" class="licenseLink" id="sla_in_page">Subscription and License Agreement</a>.
</div>
		
		
			<div id="references" class="headingAnchor">
			<h1>REFERENCES</h1>
			<ol id="reference"><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/1" class="nounderline abstract_t">Groome
 PA, Bolejack V, Crowley JJ, et al. The IASLC Lung Cancer Staging 
Project: validation of the proposals for revision of the T, N, and M 
descriptors and consequent stage groupings in the forthcoming (seventh) 
edition of the TNM classification of malignant tumours. J Thorac Oncol 
2007; 2:694.</a></li><li>Lung. In: American Joint Committee on Cancer 
Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), 
Springer, New York 2010. p.253.</li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/3" class="nounderline abstract_t">Rusch
 VW, Hawes D, Decker PA, et al. Occult metastases in lymph nodes predict
 survival in resectable non-small-cell lung cancer: report of the ACOSOG
 Z0040 trial. J Clin Oncol 2011; 29:4313.</a></li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/4" class="nounderline abstract_t">Chen
 HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome 
in non-small-cell lung cancer. N Engl J Med 2007; 356:11.</a></li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/5" class="nounderline abstract_t">Seike
 M, Yanaihara N, Bowman ED, et al. Use of a cytokine gene expression 
signature in lung adenocarcinoma and the surrounding tissue as a 
prognostic classifier. J Natl Cancer Inst 2007; 99:1257.</a></li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/6" class="nounderline abstract_t">Lau
 SK, Boutros PC, Pintilie M, et al. Three-gene prognostic classifier for
 early-stage non small-cell lung cancer. J Clin Oncol 2007; 25:5562.</a></li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/7" class="nounderline abstract_t">Kratz
 JR, He J, Van Den Eeden SK, et al. A practical molecular assay to 
predict survival in resected non-squamous, non-small-cell lung cancer: 
development and international validation studies. Lancet 2012; 379:823.</a></li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/8" class="nounderline abstract_t">Tsao
 MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance 
of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J
 Clin Oncol 2007; 25:5240.</a></li><li>Shepherd FA, Bourredjem A, 
Brambilla E, et al. Prognostic and predictive effects of KRAS mutation 
subtype in completely resected non-small cell lung cancer (NSCLC): A 
LACE-bio study. J Clin Oncol 2012; 30: (suppl; abstr 7007).</li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/10" class="nounderline abstract_t">Brock
 MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early 
recurrence in stage I lung cancer. N Engl J Med 2008; 358:1118.</a></li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/11" class="nounderline abstract_t">Chemotherapy
 in non-small cell lung cancer: a meta-analysis using updated data on 
individual patients from 52 randomised clinical trials. Non-small Cell 
Lung Cancer Collaborative Group. BMJ 1995; 311:899.</a></li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/12" class="nounderline abstract_t">Arriagada
 R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in
 patients with completely resected non-small-cell lung cancer. N Engl J 
Med 2004; 350:351.</a></li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/13" class="nounderline abstract_t">Waller
 D, Gower N, Milroy MD, et AL.. The Big Lung Trial: determining the 
value of cisplatin-based chemotherapy for all patients with non-small 
cell lung cancer (NSCLC). Preliminary results in the surgical setting 
(abstract). Proc Am Soc Clin Oncol 2003; 22:639.</a></li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/14" class="nounderline abstract_t">Scagliotti
 GV, Fossati R, Torri V, et al. Randomized study of adjuvant 
chemotherapy for completely resected stage I, II, or IIIA non-small-cell
 Lung cancer. J Natl Cancer Inst 2003; 95:1453.</a></li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/15" class="nounderline abstract_t">Douillard
 JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin 
versus observation in patients with completely resected stage IB-IIIA 
non-small-cell lung cancer (Adjuvant Navelbine International Trialist 
Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 
7:719.</a></li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/16" class="nounderline abstract_t">Winton
 T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. 
observation in resected non-small-cell lung cancer. N Engl J Med 2005; 
352:2589.</a></li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/17" class="nounderline abstract_t">Strauss
 GM, Herndon J, Maddaus MA, et AL.. Randomized clinical trial of 
adjuvant chemotherapy with paclitaxel and carboplatin following 
resection in stage IB non-small cell lung cancer (NSCLC): report of 
Cancer and Leukemia Group B (CALGB) protocol 9633 (abstract). Proc Am 
Soc Clin Oncol 2004; 23:621s.</a></li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/18" class="nounderline abstract_t">Strauss
 GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus 
carboplatin compared with observation in stage IB non-small-cell lung 
cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation 
Therapy Oncology Group, and North Central Cancer Treatment Group Study 
Groups. J Clin Oncol 2008; 26:5043.</a></li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/19" class="nounderline abstract_t">Pignon
 JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin 
evaluation: a pooled analysis by the LACE Collaborative Group. J Clin 
Oncol 2008; 26:3552.</a></li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/20" class="nounderline abstract_t">NSCLC
 Meta-analyses Collaborative Group, Arriagada R, Auperin A, et al. 
Adjuvant chemotherapy, with or without postoperative radiotherapy, in 
operable non-small-cell lung cancer: two meta-analyses of individual 
patient data. Lancet 2010; 375:1267.</a></li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/21" class="nounderline abstract_t">Butts
 CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine
 plus cisplatin compared with observation in completely resected stage 
IB and II non-small-cell lung cancer: updated survival analysis of 
JBR-10. J Clin Oncol 2010; 28:29.</a></li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/22" class="nounderline abstract_t">Bezjak
 A, Lee CW, Ding K, et al. Quality-of-life outcomes for adjuvant 
chemotherapy in early-stage non-small-cell lung cancer: results from a 
randomized trial, JBR.10. J Clin Oncol 2008; 26:5052.</a></li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/23" class="nounderline abstract_t">Jang
 RW, Le Maître A, Ding K, et al. Quality-adjusted time without symptoms 
or toxicity analysis of adjuvant chemotherapy in non-small-cell lung 
cancer: an analysis of the National Cancer Institute of Canada Clinical 
Trials Group JBR.10 trial. J Clin Oncol 2009; 27:4268.</a></li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/24" class="nounderline abstract_t">Arriagada
 R, Dunant A, Pignon JP, et al. Long-term results of the international 
adjuvant lung cancer trial evaluating adjuvant Cisplatin-based 
chemotherapy in resected lung cancer. J Clin Oncol 2010; 28:35.</a></li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/25" class="nounderline abstract_t">Früh
 M, Rolland E, Pignon JP, et al. Pooled analysis of the effect of age on
 adjuvant cisplatin-based chemotherapy for completely resected 
non-small-cell lung cancer. J Clin Oncol 2008; 26:3573.</a></li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/26" class="nounderline abstract_t">Pepe
 C, Hasan B, Winton TL, et al. Adjuvant vinorelbine and cisplatin in 
elderly patients: National Cancer Institute of Canada and Intergroup 
Study JBR.10. J Clin Oncol 2007; 25:1553.</a></li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/27" class="nounderline abstract_t">Pisters
 KM, Evans WK, Azzoli CG, et al. Cancer Care Ontario and American 
Society of Clinical Oncology adjuvant chemotherapy and adjuvant 
radiation therapy for stages I-IIIA resectable non small-cell lung 
cancer guideline. J Clin Oncol 2007; 25:5506.</a></li><li>National 
Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines 
in oncology. 
http://www.nccn.org/professionals/physician_gls/f_guidelines.asp 
(Accessed on April 01, 2014).</li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/29" class="nounderline abstract_t">Goss
 GD, O'Callaghan C, Lorimer I, et al. Gefitinib versus placebo in 
completely resected non-small-cell lung cancer: results of the NCIC CTG 
BR19 study. J Clin Oncol 2013; 31:3320.</a></li><li>Kelly K, Altorki NK,
 Eberhardt WE, et al. A randomized, double-blind phase 3 trial of 
adjuvant erlotinib (E) versus placebo (P) following complete tumor 
resection with or without adjuvant chemotherapy in patients (pts) with 
stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer 
(NSCLC): RADIANT results (abstract 7501). 2014 American Society of 
Clinical Oncology (ASCO) meeting.</li><li>Shepherd FA, Altorki NK, 
Eberhardt WE, et al. Adjuvant erlotinib (E) versus placebo (P) in 
non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying 
EGFR-sensitizing mutations from the RADIANT trial (abstract 7513). 2014 
American Society of Clinical Oncology (ASCO) meeting.</li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/32" class="nounderline abstract_t">D'Angelo
 SP, Janjigian YY, Ahye N, et al. Distinct clinical course of 
EGFR-mutant resected lung cancers: results of testing of 1118 surgical 
specimens and effects of adjuvant gefitinib and erlotinib. J Thorac 
Oncol 2012; 7:1815.</a></li><li>Pennell NA, Neal JW, Chaft JE, et al. A 
multicenter phase II trial of adjuvant erlotinib in resected early-stage
 EGFR mutation-positive NSCLC (abstract 7514). 2014 American Society of 
Clinical Oncology (ASCO) meeting</li><li><a href="http://www.uptodate.com/contents/adjuvant-systemic-therapy-in-resectable-non-small-cell-lung-cancer/abstract/34" class="nounderline abstract_t">NSCLC
 Meta-analysis Collaborative Group. Preoperative chemotherapy for 
non-small-cell lung cancer: a systematic review and meta-analysis of 
individual participant data. Lancet 2014; 383:1561.</a></li><li>Adjuvant! Online program available online at www.adjuvantonline.com (Accessed on November 08, 2011).</li></ol>
			</div>
		
	
		<div id="topicFooter">
			<div id="topicVersionRevision">Topic 4636 Version 26.0</div>
		</div>
		
	</div>	
	
	





<div style="display: block; width: 1485px; bottom: -175px;" id="footer">
	
	<div style="width: 1449px;" class="footer_row footer_gradient">
		<div id="footerTopLeft">
			
			<a href="http://www.uptodate.com/contents/license" class="footerlink licenseLink" id="sla_footer">Subscription and License Agreement</a>
			<span class="pipeSpace">|</span>
			
			<a href="http://www.uptodate.com/home/policies" target="_blank">Policies</a>
			<span class="pipeSpace">|</span>
			<a href="#" class="footerlink" id="sinfo_footer">Support Tag</a>
			
		</div>
		<div id="footer_social">
			<a id="sfiFacebook" href="https://www.facebook.com/UpToDateEBM" target="_blank" title="Facebook">Facebook</a>
			<a id="sfiTwitter" href="https://twitter.com/UpToDate" target="_blank" title="Twitter">Twitter</a>
			<a id="sfiLinkedIn" href="http://www.linkedin.com/company/uptodate?trk=hb_tab_compy_id_21924" target="_blank" title="LinkedIn">LinkedIn</a>
			<a id="sfiYouTube" href="http://www.youtube.com/uptodateebm" target="_blank" title="YouTube">YouTube</a>
		</div>
		<div class="clear"></div>
	</div>
	<div class="footer_body">
		<div class="footer_group">
			<div id="footerLogo">
				<a href="http://www.wolterskluwerhealth.com/" target="_blank">Wolters Kluwer Health</a>
			</div>
		</div>
		<div class="footer_group">
			<h4>Using UpToDate</h4>
			<div class="footer_group_col footer_first_col">
				<a href="http://www.uptodate.com/home/contact-us" target="_blank">Contact Us</a>
				<a href="http://www.uptodate.com/home/help" target="_blank">Help</a> 
			</div>
			<div class="footer_group_col footer_second_col">
				<a href="http://www.uptodate.com/home/help-demo" target="_blank">Demos</a>
				<a href="http://www.uptodate.com/home/uptodate-news" target="_blank">UpToDate News</a>
			</div>
			<div class="footer_group_col">
				<a href="http://www.uptodate.com/home/uptodate-mobile-access" target="_blank">Access Options for UpToDate</a>
				<a href="http://www.uptodate.com/home/training-resource-center" target="_blank">Training Center </a>
			</div>
		</div>
		<div class="clear"></div>
		<p>© 2014 UpToDate, Inc. All rights reserved.</p>
	</div>
	<div style="width: 1465px;" id="footerNav" class="footer_gradient">
		<a href="http://www.wolterskluwerhealth.com/" target="_blank">Wolters Kluwer Health</a> 
		<span class="pipeSpace">|</span>
		<a href="http://www.factsandcomparisons.com/" target="_blank">Facts &amp; Comparisons®</a> 
		<span class="pipeSpace">|</span>
		<a href="http://www.healthlanguage.com/" target="_blank">Health Language®</a> 
		<span class="pipeSpace">|</span>
		<a href="http://www.lexi.com/" target="_blank">Lexicomp®</a> 
		<span class="pipeSpace">|</span>
		<a href="http://www.medispan.com/" target="_blank">Medi-Span®</a> 
		<span class="pipeSpace">|</span>
		<a href="http://www.medicom.com.cn/" target="_blank">Medicom®</a> 
		<span class="pipeSpace">|</span>
		<a href="http://pharmacyonesource.com/" target="_blank">Pharmacy OneSource®</a> 
		<span class="pipeSpace">|</span>
		<a href="http://www.provationmedical.com/" target="_blank">ProVation® Medical</a> 
		<span class="pipeSpace">|</span>
		<a href="http://www.provationordersets.com/" target="_blank">ProVation® Order Sets</a> 
		 
		<div class="clear"></div>
	</div>
</div>
<div id="footerEmail">
	<span id="tooltip_container">
		<button id="closeSupportInfo"></button>		
		<span id="tooltip_content">
			<form id="frmEmlSpt">	
				Release: 22.6<br>
				Content: C22.124<br>
				Licensed To: <span class="emphasis">UpToDate Individual Web - Anthony Rifkin  </span><br>
				Support Tag:<br>[1003-108.21.187.47-1415AD357F-6.14-178359611]<br>
				<span id="serviceEmailInput">
				<p>
					<label class="infield" for="ticketNumber">Enter case reference ID</label>
					<input id="ticketNumber" type="text">
					<input id="btnEmailSupport" value="Submit" type="button">
				</p>
				<span class="error">
				
				</span>
				<p>
					<label for="rbTktOpt2">No case reference ID?
						<a href="http://www.uptodate.com/home/contact-us" target="_blank">Contact Us</a></label>
				</p>				
				</span>
				<div class="clear"></div>
			</form>
		</span>
		<span id="tooltip_arrow"></span>
	</span>
</div>


</div> <!-- rightPanel -->

<div id="leftPanel">
	
	
	
	<div style="top: 147px; height: 6612px;" id="topicOutline">
		
		
		<input id="collapse" value="Collapse Topic Outline" type="hidden">
		<input id="show" value="Show Topic Outline" type="hidden"> 
	 	<div style="top: 433.967px;" id="toggleOutline"><a href="#" title="Collapse Topic Outline"><img src="Adjuvant%20systemic%20therapy%20in%20resectable%20non-small%20cell%20lung%20cancer_files/orange_arrow_left.gif" alt=""></a></div>
		<div id="innerOutline">
		
			
					
			<h1>Topic Outline</h1>
			<div id="outline">
         <ul><li><a href="#H23" id="summRecButton" class="sr_button"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li class="plainItem"><a class="outlineLink" href="#H1">INTRODUCTION</a></li><li class="plainItem"><a class="outlineLink" href="#H2">PROGNOSIS AFTER RESECTION</a></li><li class="bulletItem"><a class="outlineLink" href="#H3">Pathologic stage</a></li><li class="bulletItem"><a class="outlineLink" href="#H4">Molecular markers</a></li><li class="dashItem"><a class="outlineLink" href="#H5">- Gene expression profiling</a></li><li class="dashItem"><a class="outlineLink" href="#H7">- k-ras and p53</a></li><li class="dashItem"><a class="outlineLink" href="#H8">- DNA methylation markers</a></li><li class="plainItem"><a class="outlineLink" href="#H9">ADJUVANT CHEMOTHERAPY</a></li><li class="bulletItem"><a class="outlineLink" href="#H10">Early clinical trials</a></li><li class="bulletItem"><a class="outlineLink" href="#H11">Platinum-based chemotherapy</a></li><li class="dashItem"><a class="outlineLink" href="#H12">- LACE meta-analysis</a></li><li class="dashItem"><a class="outlineLink" href="#H13">- ANITA</a></li><li class="dashItem"><a class="outlineLink" href="#H14">- JBR 10</a></li><li class="dashItem"><a class="outlineLink" href="#H15">- IALT</a></li><li class="dashItem"><a class="outlineLink" href="#H16">- CALGB 9633</a></li><li class="bulletItem"><a class="outlineLink" href="#H632650843">Stage IB disease</a></li><li class="bulletItem"><a class="outlineLink" href="#H17">Elderly patients</a></li><li class="bulletItem"><a class="outlineLink" href="#H18">ASCO and NCCN guidelines</a></li><li class="bulletItem"><a class="outlineLink" href="#H13804081">Choice of chemotherapy regimen</a></li><li class="plainItem"><a class="outlineLink" href="#H1604110">MOLECULARLY TARGETED AGENTS</a></li><li class="plainItem"><a class="outlineLink" href="#H20">NEOADJUVANT CHEMOTHERAPY</a></li><li class="plainItem"><a class="outlineLink" href="#PATIENT_INFORMATION">INFORMATION FOR PATIENTS</a></li><li class="plainItem"><a class="outlineLink" href="#H23">SUMMARY AND RECOMMENDATIONS</a></li><li class="plainItem"><a href="#references">REFERENCES</a></li></ul>
       </div>
       
         <h1>
         	
			
				<div id="ONC/4636" class="openRelatedGraphics" rel="outline_link">
					GRAPHICS
					<a href="#" title="View All Related Graphics" class="graphics_icon">
						View All
					</a>
				</div>
			
         </h1>
       <div id="relatedGraphics">
         <ul><li class="plainItem"><div id="ONC/4636|FIG" class="openRelatedGraphics"><a title="FIGURES" href="#">FIGURES</a></div></li><li class="bulletItem"><a href="http://www.uptodate.com/contents/image?imageKey=ONC/73088&amp;topicKey=ONC%2F4636&amp;source=outline_link" title="figure 1" class="graphic graphic_figure">Nonsmall cell lung ca survival by TNM gp</a></li><li class="plainItem"><div id="ONC/4636|TAB" class="openRelatedGraphics"><a title="TABLES" href="#">TABLES</a></div></li><li class="bulletItem"><a href="http://www.uptodate.com/contents/image?imageKey=ONC/80099&amp;topicKey=ONC%2F4636&amp;source=outline_link" title="table 1" class="graphic graphic_table">Lung cancer TMN staging 7th edition</a></li><li class="bulletItem"><a href="http://www.uptodate.com/contents/image?imageKey=ONC/90104&amp;topicKey=ONC%2F4636&amp;source=outline_link" title="table 2" class="graphic graphic_table">Adjuvant chemotherapy trials</a></li></ul>
       </div>
       
       
       
         <h1>RELATED TOPICS</h1>
       <div id="relatedTopics">
         <ul><li class="plainItem"><a href="http://www.uptodate.com/contents/comprehensive-geriatric-assessment-for-patients-with-cancer?source=related_link" class="medical medical_review">Comprehensive geriatric assessment for patients with cancer</a></li><li class="plainItem"><a href="http://www.uptodate.com/contents/management-of-stage-i-and-stage-ii-non-small-cell-lung-cancer?source=related_link" class="medical medical_review">Management of stage I and stage II non-small cell lung cancer</a></li><li class="plainItem"><a href="http://www.uptodate.com/contents/management-of-stage-iii-non-small-cell-lung-cancer?source=related_link" class="medical medical_review">Management of stage III non-small cell lung cancer</a></li><li class="plainItem"><a href="http://www.uptodate.com/contents/overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-non-small-cell-lung-cancer?source=related_link" class="medical medical_review">Overview of the initial evaluation, diagnosis, and staging of patients with suspected non-small cell lung cancer</a></li><li class="plainItem"><a href="http://www.uptodate.com/contents/non-small-cell-lung-cancer-the-basics?source=related_link" class="medical medical_basics">Patient information: Non-small cell lung cancer (The Basics)</a></li><li class="plainItem"><a href="http://www.uptodate.com/contents/non-small-cell-lung-cancer-treatment-stage-i-to-iii-cancer-beyond-the-basics?source=related_link" class="medical medical_patient">Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)</a></li><li class="plainItem"><a href="http://www.uptodate.com/contents/non-small-cell-lung-cancer-treatment-stage-iv-cancer-beyond-the-basics?source=related_link" class="medical medical_patient">Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)</a></li><li class="plainItem"><a href="http://www.uptodate.com/contents/systemic-chemotherapy-for-cancer-in-elderly-persons?source=related_link" class="medical medical_review">Systemic chemotherapy for cancer in elderly persons</a></li><li class="plainItem"><a href="http://www.uptodate.com/contents/systemic-therapy-for-advanced-non-small-cell-lung-cancer-with-an-activating-mutation-in-the-epidermal-growth-factor-receptor?source=related_link" class="medical medical_review">Systemic therapy for advanced non-small cell lung cancer with an activating mutation in the epidermal growth factor receptor</a></li><li class="plainItem"><a href="http://www.uptodate.com/contents/systemic-therapy-for-the-initial-management-of-advanced-non-small-cell-lung-cancer-without-a-driver-mutation?source=related_link" class="medical medical_review">Systemic therapy for the initial management of advanced non-small cell lung cancer without a driver mutation</a></li><li class="plainItem"><a href="http://www.uptodate.com/contents/treatment-protocols-for-non-small-cell-lung-cancer?source=related_link" class="medical medical_review">Treatment protocols for non-small cell lung cancer</a></li><li class="plainItem"><a href="http://www.uptodate.com/contents/tumor-node-metastasis-tnm-staging-system-for-non-small-cell-lung-cancer?source=related_link" class="medical medical_review">Tumor node metastasis (TNM) staging system for non-small cell lung cancer</a></li></ul>
       </div>
       
					
		
		</div>
	</div>
	
		<div id="graphics_overlay">
	<span id="graphics_overlay_background"></span>
	<div id="graphics_overlay_container">
		<div id="graphics_toolbar">
			



<!-- TC:SEARCH_RESULT -->







<ul id="graphics_toolbar_links">
	
	<li>
		<a target="_blank" href="" id="exportPwrPntLink">Export to PowerPoint</a>
	</li>
	
	
	<li>
		<a target="_blank" href="" id="graphicsPrintLink">Print</a>
	</li>
	
	
	<li>
		<a target="_blank" href="" id="graphicsEmailLink">Email</a>
	</li>
		
	<li>
		<a target="_blank" href="" id="graphicsFullViewLink">Full View</a>
	</li>
	<li>
		<a id="graphicsFeedback" href="#">Feedback	</a>
	</li>	
</ul>	
<ul id="graphics_toolbar_info">
	<li id="graphicsFor">
		
	</li>
</ul>
<span id="graphicsForTxt">Graphics for:&nbsp;</span>
<p style=""></p>				
		</div>
		<div id="overlay_content" style="overflow-y: scroll;"></div>
	</div>
	<div id="overlay_close"></div>
</div>

	
	
</div> <!-- leftPanel -->



 <a style="bottom: 100px;" id="topicFeedbackBug" href="#">Topic Feedback</a>


<div style="top: 147px; height: 6620px;" class="ui-draggable" id="dragbar" title="Drag here to resize the topic outline"></div>














<div id="versionDetails"><p>





All topics are updated as new information becomes available. Our peer 
review process typically takes one to six weeks depending on the issue.

	
	
	

</p></div>

	


	<script type="text/javascript">
	var $SAT = $SAT || [];
	$SAT.push(['setContent','user_identity','Professional_Customer']);
	$SAT.push(['setContent','user_ip_address','108.21.187.47']);
	$SAT.push(['setContent','user_language','en']);
	$SAT.push(['setContent','user_country','US']);
	$SAT.push(['setContent','user_display_format','BROWSER_DEFAULT']);
	$SAT.push(['setContent','search_type','PLAIN_TEXT']);
	$SAT.push(['setContent','source','see_link']);
	$SAT.push(['setContent','search_term','lung cancer treatment']);
	$SAT.push(['setContent','topic_id','4636']);
	$SAT.push(['setContent','topic_content_version','22.124']);
	$SAT.push(['setContent','topic_title','Adjuvant systemic therapy in resectable non-small cell lung cancer']);
	$SAT.push(['setContent','program_id','6']);
	$SAT.push(['setContent','secondary_program_id','14']);
	$SAT.push(['setContent','program_access_type','LG']);
	$SAT.push(['setContent','secondary_program_access_type','PR']);
	$SAT.push(['setUser', '178359611']);
	(function() {
		var sa = document.createElement('script'); sa.type = 'text/javascript';
		sa.src = 'http' + ('https:' == document.location.protocol ? 's' : '') + '://scout.uptodate.com/p4kh9-2/sat.ashx';
		(document.getElementsByTagName('head')[0] || document.getElementsByTagName('body')[0]).appendChild(sa);
	})();
</script>




<div id="fancybox-tmp"></div><div id="fancybox-loading"><div></div></div><div id="fancybox-overlay"></div><div id="fancybox-wrap"><div id="fancybox-outer"><div class="fancybox-bg" id="fancybox-bg-n"></div><div class="fancybox-bg" id="fancybox-bg-ne"></div><div class="fancybox-bg" id="fancybox-bg-e"></div><div class="fancybox-bg" id="fancybox-bg-se"></div><div class="fancybox-bg" id="fancybox-bg-s"></div><div class="fancybox-bg" id="fancybox-bg-sw"></div><div class="fancybox-bg" id="fancybox-bg-w"></div><div class="fancybox-bg" id="fancybox-bg-nw"></div><div id="fancybox-content"></div><a id="fancybox-close"></a><div id="fancybox-title"></div><a href="javascript:;" id="fancybox-left"><span class="fancy-ico" id="fancybox-left-ico"></span></a><a href="javascript:;" id="fancybox-right"><span class="fancy-ico" id="fancybox-right-ico"></span></a></div></div><div aria-labelledby="ui-dialog-title-findInPage" role="dialog" tabindex="-1" class="ui-dialog ui-widget ui-widget-content ui-corner-all findInPageDialog ui-draggable" style="display: none; z-index: 1000; outline: 0px none;"><div style="-moz-user-select: none;" unselectable="on" class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span style="-moz-user-select: none;" unselectable="on" id="ui-dialog-title-findInPage" class="ui-dialog-title">Find in Topic</span><a style="-moz-user-select: none;" unselectable="on" role="button" class="ui-dialog-titlebar-close ui-corner-all" href="#"><span style="-moz-user-select: none;" unselectable="on" class="ui-icon ui-icon-closethick">close</span></a></div><div class="ui-dialog-content ui-widget-content" style="display: block;" id="findInPage">
	<div id="findInPageInput">
		<div id="fitWrap"><input id="findInPageTerm" type="text"></div>
		<input id="findInPageFind" class="bluBlk" value="Find" type="button">
		<div class="clear"></div>
		<div id="clrTxt" title="Clear Search Term" style="display:none;"></div>
	</div>
	 <div id="findInPageCtrls">
	 	<span id="count" title="Number of Results">0</span>
	 	<a href="javascript:;" id="syn" title="Show or Hide Term Synonyms">Find synonyms</a>
	 	<span id="backfor">
			<a href="javascript:;" id="back" title="Previous Result"></a>
			<a href="javascript:;" id="forward" title="Next Result"></a>
			<div class="clear"></div>
		</span>
		<p style="display:none;">
			<input name="findInPageSearchType" value="syn" checked="checked" type="radio"><span class="icontxt">Find synonyms</span>
			<input name="findInPageSearchType" value="exact" type="radio"><span class="icontxt">Find exact match</span>
		</p>
		<div class="clear"></div>
	 </div>
	 
	
</div></div><div id="searchbox_dd_dropdown">
			<ul id="searchbox_dd_dropdown_topics">
				<li id="searchoption_topic_all" class="active">All Topics</li>
				<li id="searchoption_topic_adult">Adult </li>
				<li id="searchoption_topic_pediatric">Pediatric </li>
				<li id="searchoption_topic_patient">Patient </li>
			</ul>
			<ul id="searchbox_dd_dropdown_graphics">
				<li id="searchoption_graphics">Graphics</li>
			</ul>
		</div><ul style="top: 116px; left: 10px; width: 459px;" id="autoCompleteList"></ul><div id="greyBarShadow" class="absShadow" style="display: none;"></div><div id="overflowDropdown"><ul></ul></div></body></html>